Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 2.6 to 0.
-
Busy address KBO
70 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
ESTEVE PHARMACEUTICALS from Jette, company number BE0543727164, closed financial year 2024 with a result of € 142,934 after tax. For that financial year ESTEVE PHARMACEUTICALS recorded revenue of € 1.2 million and equity of € 834,379. Compared with financial year 2023, the result moved from € -92,709 to € 142,934. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2025.
€ 834,379
▲ 21% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 142,934
▲ still € 92,709 loss in 2023
Profit after tax over the fiscal year.
€ 0
▼ 100% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 815,829.
People and assets in 2024
0
▼ 0.3 vs 2023
Average over the fiscal year, from the social balance sheet.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 85,878
▲ 38% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 25 days on average.
€ 17,736
▲ € 14,072 vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 5,058,992 | € 6,393,656 | € 1,326,048 | € 1,196,285 | ▼ 10% |
| Profit after taxes | € -525 | € 271,478 | € -92,709 | € 142,934 | ▲ € 235,643 |
| Equity | € 512,676 | € 784,154 | € 691,445 | € 834,379 | ▲ 21% |
| Total debts | € 2,421,050 | € 2,392,897 | € 3,310,247 | € 600,224 | ▼ 82% |
| Cash | € 427,962 | € 814,537 | € 756,872 | € 0 | ▼ 100% |
| Retained profit | € 494,126 | € 765,604 | € 672,895 | € 815,829 | ▲ 21% |
| Balance sheet total | € 2,933,726 | € 3,177,051 | € 4,001,692 | € 1,434,602 | ▼ 64% |
| Employees (FTE) | 3 | 2.6 | 0.3 | 0 | ▼ 0.3 |
Key figures of ESTEVE PHARMACEUTICALS, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to ESTEVE PHARMACEUTICALS?
What happened at ESTEVE PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 142,934. Source: NBB ↗
- Jacob Tolstrup became a director. NBB
- Ivan Hagay became a director. NBB
- New establishment in Machelen (Brab.). KBO
- New establishment in Jette. KBO
- Start of the company according to the CBE. KBO
In short
From € 525 loss in 2021 to € 142,934 profit in 2024.
Paid € 129,841 in corporate taxes since 2021.
Best year ever: 2022, with € 271,478 profit.
Pays suppliers within 25 days on average.
A new publication or filing at ESTEVE PHARMACEUTICALS? We notify you, reason included.
Follow ESTEVE PHARMACEUTICALSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ESTEVE PHARMACEUTICALS are Jacob Tolstrup and Ivan Hagay.
Directors
According to the 2024 annual accounts
Jacob Tolstrup
Director
since 2025
Ivan Hagay
Director
since 2025
Establishments
Establishment units
Physical locations of this company
Burgemeester Etienne Demunterl. 5 box 10
1090 Jette
Pegasuslaan 5
1831 Machelen (Brab.)
Active since 27 January 2014
Burgemeester Etienne Demunterl. 5/10
1090 Jette
Active since 2 January 2014
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 70 companies are registered at this address.
All companies at this address →BINWEY
€ 808,048 gross margin · 2025
CARROSSERIE KARREVELD
€ 2.9 million gross margin · 2024
Medtronic Belgium
€ 196.3 million revenue · 2025
LANSON REAL ESTATE
€ 12.4 million gross margin · 2025
BAMEL
€ 166,815 gross margin · 2025
+65 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0543.727.164
- VAT number
- BE 0543.727.164
- Registered office
- Burgemeester Etienne Demunterl. 5 bus 10, 1090 Jette
- Names & denominations
- ESTEVE PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 January 2014
- Peppol
- Active · Active since 21 Nov 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren